Targeted Genetics Sells AAV, Manufacturing Tech to Genzyme for $7M
September 17, 2009
Targeted Genetics Sells AAV, Manufacturing Tech to Genzyme for $7M
As part of the deal, which is expected to give Targeted Genetics enough cash to continue operations through 2010, the firm licensed back the technology and IP for certain drug-development efforts, including its RNAi-based Huntington’s disease program.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News - RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News - Merck Remains Committed to RNAi Despite Shuttering Its California Facility
August 4, 2011 / Gene Silencing News - Quark, Pfizer Amend Deal for Ocular Disease Drug on Less-than-Ideal Phase II Data
March 24, 2011 / Gene Silencing News - Alnylam, Max Planck Settle Suit Over Tuschl IP
March 17, 2011 / Gene Silencing News